TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05461560

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sucrose solution
Description: 50 g of sucrose dissolved in 500 ml of tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed extract in sucrose solution
Description: 1 g of seaweed extract in solution of 50 g of sucrose in 500 ml of tap water
Study: NCT05352529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The MapHabit system
Description: The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device.
Study: NCT05315856

Intervention type: BIOLOGICAL
Intervention: either BNT162b2 or ChAdOx1 vaccine
Description: Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
Study: NCT05352529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dementia educational videos
Description: Investigators collected publicly available educational videos regarding dementia-related caregiving and support. The videos were made available to participants through compatible tablets.
Study: NCT05808647

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5-day controlled metabolic dietary intake
Description: Over 5-days, all food will be provided from the metabolic kitchen and participants will be instructed to eat all of the food provided each day and only the food provided each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-day controlled metabolic dietary intake
Description: Over 5-days, all food will be provided from the metabolic kitchen and participants will be instructed to eat all of the food provided each day and only the food provided each day.
Study: NCT06078683

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C8 Ketone Supplement
Description: Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the supplement twice a day for 6 weeks. The supplement is a C8 Ketone Diester supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein. For the proposed studies all participants will drink 5.4 oz of supplement, delivering 50g of C8 Ketone Supplement daily in a split serving fashion where half will be consumed in the morning with breakfast, and the other half with lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the placebo twice a day, once at breakfast, and once around lunch time for 6 weeks. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any ketones (BHB), which will be replaced with a similar caloric content of fat in the form of canola oil.
Study: NCT04815668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Description: Sterile single-use stainless steel needles (size 0.35 mm × 55 mm) (YiDaiFu brand, Suzhou Tianyi Acupuncture Instrument Co., Ltd., Suzhou, China) will be utilized. Participants in lateral position, the acupoints area will be sterilized with 75% alcohol. To stimulate SPG, the needles will be inserted in the medial superior anterior direction to a depth of approximately 55 mm33 until the participants report a special sensation radiating toward the nose or the upper teeth. After that, the needle will be withdrew slightly. The needles will be retained for 30 minutes after three stimulation. Rescue medication are permitted when participants feel that their symptoms are intolerable.
Study: NCT06078683

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester Acute
Description: Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink two servings of the supplement at once (50g total C8 Ketone Supplement), and images obtained before and after consumption. The supplement is a C8 Ketone Supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acute
Description: Participants will undertake a controlled feeding intervention where they will drink two servings of the placebo at once (50g total placebo), and images obtained before and after consumption. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any BHB, which will be replaced with a similar caloric content of fat in the form of canola oil.
Study: NCT05367687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab、Rivoceranib
Description: Camrelizumab: 200 mg, intravenous infusion. Rivoceranib: 250 mg, oral.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: Camrelizumab: 200 mg, intravenous infusion.
Study: NCT06018831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine and Ultrasound Screening
Description: When an infant was born, he/she will receive the first urine and ultrasound screening in 3 months in Kunshan/Qidong City Maternal and Child Health Hospital.In Kunqi Cohort, 9,000 will complete 3 years follow-up(urine screening once every year, another ultrasound screening in 24-30 months). Urine sample (50ml) will be stored only once within one year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study.1,000 children will complete 6 year follow-up(receive urine and ultrasound screening once every year). Urine sample (50ml) will be stored once a year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study. The 14 urine test items include: leukocytes, urobilinogen, microalbumin, protein, bilirubin, glucose, ascorbic acid, specific gravity, ketone bodies, nitrite, creatinine, pH, occult blood, and urinary calcium. Ultrasound test will screen for kidneys, ureters and the bladder.
Study: NCT06639347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102
Description: SHR-A2102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab injection
Description: Adebrelimab injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068 injection
Description: SHR-8068 injection
Study: NCT04528082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Participants will receive apremilast orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast
Description: Participants will receive apremilast orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the matching placebo orally.
Study: NCT04815668

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture group
Description: The acupuncture procedure will be similar to that of the acupuncture group. After sterilizing the skin, the 0.35 × 25 mm disposable needle will be vertically inserted at SPG acupoint about 3-5 mm. No needle manipulation will be conducted to avoid the deqi response. Rescue medication are permitted when participants feel that their symptoms are intolerable.

Intervention type: OTHER
Group type: OTHER
Intervention: Rescue medication group
Description: Participants in the rescue medication group do not receive acupuncture treatment during the study period. They will be only allowed to use rescue medication. They have the option of 4 weeks (up to 8 sessions) of acupuncture free of charge at the end of the follow-up period.
Study: NCT05293509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2/day i.v.- by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2/day i.v.- by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 25 mg/m2/day i.v.-by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 100 mg/m2 IV-by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 100 mg/m2 IV-by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Four doses of rituximab at a dose of 375 mg/m2- by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 110 mg/m2 i.v-by vein
Study: NCT05350267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HALO
Description: Health and Lifestyle Behaviors in Offspring, or HALO is designed for mothers who recently had bariatric surgery who have a school-aged child. HALO focuses on providing each mother with education and parenting strategies to improve her child's healthy lifestyle behaviors, such as her child's eating and physical activity, while she is engaged in her own lifestyle behavior change after bariatric surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
Study: NCT05793151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENDURE
Description: ENDURE provides patient education through the ENDURE Patient Resource Guide and social support by linking patients to community resources (patient-level), standardizes discussions about expectations for PORT and clinical documentation to enhance communication and care coordination within and across interprofessional cancer teams (team-level), and implements referral tracking across fragmented health systems (organization-level). To facilitate care coordination, ENDURE modifies existing standard of care patient navigation (an evidence-based intervention that addresses barriers to timely cancer care) by adding PORT-focused navigation at three key care transitions: into the cancer care system; from inpatient to outpatient after surgery; and from the surgical team to the radiation oncology team.
Study: NCT05156112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure Device
Description: Each PAP treatment initiation meeting will include 1) mask fitting; 2) psycho-education to what to expect and reviewing PAP machine problem solving; and 3) setting up correct PAP treatment (e.g., auto PAP or in rare conditions, bi-level PAP).
Study: NCT06450535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous onlay bone block harvesting from retromolar bone in anterior maxilla
Description: Surgical protocol ( retromolar bone harvesting) After injecting local anesthesia a crestal incision is done, from a point on the occlusal surface along the external oblique ridge and extending anteriorly and inferiorly through the buccal mucosa, parallel to the gingival margin of the mandibular molars.~The subperiosteal dissection extend to expose the ascending ramus and the retromolar region With the aid of surgical carbide burs, two proximal vertical cuts penetrating the cortex of the external oblique ridge.~The depth of penetration of the posterior cut did not exceed 2.5 mm to avoid injury to the inferior alveolar nerve.~By using microsaw , an inferior cut of 3.2 mm in depth joining the anterior and posterior vertical cuts was done.~Small perforations of 3-4 mm in depth were performed on the superior aspect of the external oblique ridge using 1 mm drill bur.~Finally, the block was sheared off using a chisel.
Study: NCT05051657

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU express plus
Description: PKU express plus is a powdered protein substitute for the dietary management of PKU. It is formulated in a variety of flavours to provide a convenient, low volume, lower calorie, pre-measured protein substitute, containing a full micronutrient profile.
Study: NCT06411691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRAS Vaccine with Poly-ICLC adjuvant
Description: SLP mKRASvax with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22 in Cycle 1 (Prime Phase) and on day 1 in cycle 4 and every other cycle and beyond (Boost Phase). Up to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: 75 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on day 1 and day 15 during Cycle 1 in Prime Phase and on day 1 and day 15 of every cycle in the Boost Phase beginning on Cycle 2 (for a maximum of 2 years from initial vaccination).~Drug: 75 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: 240 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on Cycle 1 day 1 in Prime Phase and on Cycle 2 day 1 in the Boost Phase.~Drug: 240 mg IV
Study: NCT05561140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor Oral Tablet
Description: Synthetic small molecule supplied as 500 mg tablets, administered Orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05293509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 110 mg/m2 i.v-by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy)
Description: by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy)
Description: by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (or cyclosporine)
Description: by vein
Study: NCT06450535

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous cortical shell technique from retromolar bone in anterior maxilla
Description: The harvested cortical plate was then split longitudinally in two parts using a microsaw, and thinned with the bone scraper to achieve a plate of 1 mm thickness.~The plate was fixed at a distance from the residual ridge with 2 screws. Autogenous bone particles, collected with the bone scraper, were tightly packed into the gap between the plate and the recipient site.
Study: NCT06353971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Briquilimab
Description: Subcutaneous Injection
Study: NCT05659251

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy
Description: Serplulimab 4.5mg/kg, IV, Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Preoperative neoadjuvant therapy for 3 cycles, one cycle every 21 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive Ivor-Lewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy.~The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sample
Description: Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use.~5 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery.~Tumour sample will be collected before neoadjuvant therapy and after surgery.
Study: NCT05293509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (or cyclosporine)
Description: by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: by vein
Study: NCT06038474

Intervention type: DRUG
Group type: OTHER
Intervention: Descartes-08
Description: Autologous T-cells expressing a chimeric antigen receptor directed to BCMA
Study: NCT06325709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Base-edited hematopoietic stem and progenitor cells
Description: Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. The product is administered intravenously as a single infusion. This product is under an IND.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). Conditioning will be given intravenously over 3 days with an approximate total dose of 12mg/kg. Drug levels obtained will be obtained to achieve the targeted total busulfan AUC of 65,000 ng/mL x hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Mucositis Prophylaxis Agent: Intravenous infusion of keratinocyte growth factor (Palifermin) at 60 mcg/kg/day before (Days -7 to Day -5 administration of busulfan and (Days 1 to 3) post-busulfan administration to prevent oral mucositis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
Study: NCT06636266

Intervention type: OTHER
Intervention: Survey using a questionnaire.
Description: This research will examine any potential differences in the professional identity of Scottish chiropractors utilising the Chiropractic Professional Identity Embodiment Scale (CPIES) and the Subtype Orientation Scale (CPISOS).

Intervention type: OTHER
Intervention: Survey using a questionnaire.
Description: This research will examine any potential differences in the professional identity of Scottish chiropractors utilising the Chiropractic Professional Identity Embodiment Scale (CPIES) and the Subtype Orientation Scale (CPISOS).
Study: NCT04883957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Film-coated tablets administered orally as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Film-coated tablets administered orally as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Film-coated tablets administered orally as specified in the treatment arm.
Study: NCT05014412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody
Study: NCT04941781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPE-307
Description: Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307.~Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging.
Study: NCT04704336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-shifting strategy for HTN control (TASSH) protocol
Description: The TASSH protocol include the following 4 steps: 1). Identify HIV patients with uncontrolled HTN: trained HIV nurses will take patients' medical history (whether or not they have a diagnosis of diabetes, heart attack, stroke, heart failure, smoking). 2) Next, they will measure the patients' weight, height, waist circumference and BP with a valid automated device following standard procedures and then conduct lab tests with point-of-care testing on blood glucose, lipids and urine dip stick. 3) Initiate lifestyle counseling and medication treatment every 1-3 months: The nurses will next counsel eligible patients on lifestyle behaviors for 20 to 30 minutes (increased intake of fruits and vegetables, moderate physical activity and reduce salt intake). 4). Refer patients with complicated HTN to physicians for further care
Study: NCT05120271

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T Cells
Description: Five dose levels each with LD chemotherapy
Study: NCT04734106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desert Harvest Aloe Vera Capsules
Description: 600 mg pure, freeze-dried aloe vera super-concentrate with a minimum of 200 mg glycosaminoglycan per capsule.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: 550mg of Avicel microcrystalline cellulose per two-piece, hard-shelled gelatin capsule.
Study: NCT06081517

Intervention type: BEHAVIORAL
Intervention: Social Determinants of Health and toxicity questionnaires
Description: Collect detailed clinical, and social data from patients to identify significant contributors of disparate survival and toxicity outcomes.

Intervention type: BEHAVIORAL
Intervention: Social Determinants of Health and toxicity questionnaires
Description: Collect detailed clinical, and social data from patients to identify significant contributors of disparate survival and toxicity outcomes.